• Asian Pacific Journal of Cancer Prevention
• /
• v.17 no.9
• /
• pp.4527-4531
• /
• 2016

Background: PTEN protein is one of the most important tumour suppressor factors which is detectable by immunohistochemistry. The goal of the present study was to investigate the prognostic role of PTEN gene expression in breast cancer patients. Materials and Methods: This descriptive-analytical study was conducted on 100 breast cancer patients referred to Sabzevar hospitals in the north-east of Iran between 2010 and 2011, who were followed up to 2015. PTEN gene expression in tissue samples was determined using specific monoclonal antibodies and data were analyzed using Chi-square test and Fisher's exact test. Patient survival was analyzed after 4 years of follow-up using the Cox regression model. Results: PTEN gene expression was evident in 70 of 100 cnacer samples but was found at high levels in all non-cancer samples. There was an inverse significant relationship between PTEN gene expression and tumour stage or tumour grade (p<0.001). The expression of PTEN in invasive ductal tumours was lower than in non-invasive tumours. There was also an inverse significant relationship between the hazard of death and PTEN gene expression (p<0.001). In addition, there was an inverse significant relationship between tumour stage and hazard of death (p<0.001). Conclusion: These findings indicate that lack of PTEN gene expression can be a sign of a worse prognosis and poor survival in breast cancer cases.

• The Journal of the Korea Contents Association
• /
• v.15 no.2
• /
• pp.313-323
• /
• 2015

This study was performed to examine the prevalence of and risk factors for depression and anxiety among breast cancer survivors in their 40s. Completed questionnaires were collected from 609 breast cancer survivors in their 40s who agreed to participate the study. The mean scores of CES-D and GAD-7 were 16.35(SD=9.24) and 4.25(SD=4.17), respectively. Nearly 47.7% of the participants had depression and 10.3% had anxiety. The mean score of pain severity was 1.91(SD=1.60) and 10.9% of the participants reported more than moderate pain. The final model in the hierarchical regression analysis showed that pain interference, unemployment, the type of live-in partner, and past psychiatric disease were the significant risk factors for depression, and pain interference, unemployment and past psychiatric disease for anxiety. These results show the prevalence of depression and anxiety among breast cancer survivors in their 40s is high and suggest appropriate psychosocial intervention should be provided for high risk groups based on those risk factors.

• Journal of Society of Preventive Korean Medicine
• /
• v.26 no.1
• /
• pp.11-23
• /
• 2022

Objectives : The aim of this study was to develop a clinical pathway (CP) model for the integrative treatment of non-invasive breast cancer, with western medicine and Korean traditional medicine. Methods : The checklist model was composed in four types according to the target patients: DCIS inpatients, DCIS outpatients, LCIS inpatients, LCIS outpatients. The vertical axis of the pathway consists of 11 categories of actions applied to the patient. The horizontal axis was in accordance with the flow of time, comprising three periods during inpatient care and seven periods during outpatient care. In addition, CP was also composed in flow chart form. The pathway model was developed through a literature review of clinical practice guidelines, conference publications, papers, books, and websites. Results : The integrative CP model for non-invasive breast cancer was developed. Conclusions : The goal of the CP suggested in this study was to improve non-invasive breast cancer patients' quality of life and to supplement conventional treatment, by alleviating the side effects. The model developed through this study could serve as the basis when developing CPs in a real-world integrative medical environment. This could lead to a reduction in cost and time for CP development, thus bringing about efficiency in the clinical setting.

• Genomics & Informatics
• /
• v.21 no.2
• /
• pp.20.1-20.10
• /
• 2023

Aromatase inhibitors (AI) are drugs that are widely used in treating estrogen receptor (ER)-positive breast cancer patients. Drug resistance is a major obstacle to aromatase inhibition therapy. There are diverse reasons behind acquired AI resistance. This study aims at identifying the plausible cause of acquired AI resistance in patients administered with non-steroidal AIs (anastrozole and letrozole). We used genomic, transcriptomic, epigenetic, and mutation data of breast invasive carcinoma from The Cancer Genomic Atlas database. The data was then separated into sensitive and resistant sets based on patients' responsiveness to the non-steroidal AIs. A sensitive set of 150 patients and a resistant set of 172 patients were included for the study. These data were collectively analyzed to probe into the factors that might be responsible for AI resistance. We identified 17 differentially regulated genes (DEGs) among the two groups. Then, methylation, mutation, miRNA, copy number variation, and pathway analyses were performed for these DEGs. The top mutated genes (FGFR3, CDKN2A, RNF208, MAPK4, MAPK15, HSD3B1, CRYBB2, CDC20B, TP53TG5, and MAPK8IP3) were predicted. We also identified a key miRNA - hsa-mir-1264 regulating the expression of CDC20B. Pathway analysis revealed HSD3B1 to be involved in estrogen biosynthesis. This study reveals the involvement of key genes that might be associated with the development of AI resistance in ER-positive breast cancers and hence may act as a potential prognostic and diagnostic biomarker for these patients.

• Nutrition Research and Practice
• /
• v.17 no.5
• /
• pp.917-933
• /
• 2023

BACKGROUND/OBJECTIVES: As peanuts germinate, the content of the components beneficial to health, such as resveratrol, increases within the peanut sprout. This study examined whether the ethanol extract of peanut sprout tea (PSTE) inhibits breast cancer growth and metastasis. MATERIALS/METHODS: After orthotopically injecting 4T1 cells into BALB/c mice to induce breast cancer, 0, 30, or 60 mg/kg body weight/day of PSTE was administered orally. Angiogenesis-related protein expression in the tumors and the degree of metastasis were analyzed. 4T1 and RAW 264.7 cells were co-cultured, and reverse transcription polymerase chain reaction was performed to measure the crosstalk between breast cancer cells and macrophages. RESULTS: PSTE reduced tumor growth and lung metastasis. In particular, PSTE decreased matrix metalloproteinase-9, platelet endothelial cell adhesion molecule-1, vascular endothelial growth factor-A, F4/80, CD11c, macrophage mannose receptor, macrophage colony-stimulating factor, and monocyte chemoattractant protein 1 expression in the tumors. Moreover, PSTE prevented 4T1 cell migration, invasion, and macrophage activity in RAW 264.7 cells. PSTE inhibited the crosstalk between 4T1 cells and RAW 264.7 cells and promoted the macrophage M1 subtype while inhibiting the M2 subtype. CONCLUSIONS: These results suggest that PSTE blocks breast cancer growth and metastasis to the lungs. This may be because the PSTE treatment inhibits the crosstalk between mammary cancer cells and macrophages and inhibits the differentiation of macrophages into the M2 subtype.

• Proceedings of the PSK Conference
• /
• 2002.10a
• /
• pp.98-114
• /
• 2002

The completion of the draft sequence of the human genome has provided us with a partial list of known and putative human genes, the total number of which is estimated between 30, 000 and 45, 000 (1, 2). These genes provide many potential targets for drugs, some of which may be useful in stopping the growth of cancers. The development of gene-targeting anticancer drugs could be greatly facilitated by the ability to narrow down the list of human genes to those that are necessary for the growth of tumor cells. (omitted)

• Proceedings of the Zoological Society Korea Conference
• /
• 2001.10a
• /
• pp.205.1-205
• /
• 2001

No Abstract, See Full Text

• 대한세포병리학회:학술대회논문집
• /
• 1992.11a
• /
• pp.10.1-10.1
• /
• 1992

• Proceedings of the Korean Society of Life Science Conference
• /
• 2003.05a
• /
• pp.87-87
• /
• 2003

• Proceedings of the Korean Nuclear Society Conference
• /
• 2005.10a
• /
• pp.864-865
• /
• 2005